The clinical relevance of KRAS gene mutation in non-small-cell lung cancer
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: There are conflicting data on the potential prognostic and predictive role of mutant KRAS in non-small-cell lung cancer (NSCLC). RECENT FINDINGS: KRAS is the most frequently mutated oncogene in lung adenocarcinoma patients of non-Asian ethnicity. Novel data also revealed that allelic variants of mutant KRAS are different concerning their biochemistry, which may influence their prognostic and predictive role in NSCLC. Though mutant KRAS is not the target of molecular therapy yet, a molecular diagnostic algorithm involving KRAS determination can define a subgroup of tumors where no further diagnostic test is necessary due to the exclusivity of this driver oncogene mutation. Recent data indicated that the prognostic role of mutant KRAS in lung adenocarcinomas in Asian patients is evident, while more research is neccessary in non-Asian populations. Studies also suggest the potential predictive role of mutant KRAS in the context of chemosensitivity of NSCLC which may depend on the individual drug types. Recent data on the negative predictive role of KRAS mutation on the efficacy of EGFR tyrosine kinase inhibitor (TKI) therapies confirm previous findings. SUMMARY: Studies on the prognostic and predictive role of mutant KRAS in lung adenocarcinoma must be extended to the analysis of the potential role for allelic variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · cited 1×
“In NSCLC various types of molecular mechanisms other than KRAS mutation seem to be operational during the development of resistance to EGFR TKI including development of novel EGFR resistance mutation (T790 M), HER2- or MET amplifications [36].”
BackgroundEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 2×
“The exception is B-RAF mutation, which can occur together with KRAS in NSCLC unlike in colorectal cancer [9].”
BackgroundThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578 · cited 1×
“acid changes are the predominant in KRAS, while in nonsmokers G12D, G13D and G12S mutations [5].”
Background
Cited by
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Chen, N., Fang, W., Lin, Z., Peng, P., Wang, J., Zhan, J., Hong, S., Huang, J., Liu, L., Sheng, J., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2005-z · Cited by 288
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
Current therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
“KRAS protein, encoded by the KRAS proto-oncogene, is a small guanine triphosphatase (GTPase) that serves as a binary switch in signal transduction for most receptor tyrosine kinases including EGFR, MET, or ALK, and plays a key role in regulating various cell functions [4, 5].”
BackgroundInfluentialK-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
Metadata
- Authors
- Tímár, J.
- Venue
- Current Opinion in Oncology
- Published
- 2014-03
- Volume
- 26
- Issue
- 2
- Pages
- 138-144
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W2014211009
- Cited by
- 59
- References
- 13
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. https://app.cochat.ai/papers/10.1097/cco.0000000000000051
- The paper
- Tímár, J. (2014). The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Current Opinion in Oncology. https://doi.org/10.1097/cco.0000000000000051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.